Skip to main content
HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial
Published Web Location
http://europepmc.org/articles/PMC4176446?pdf=renderNo data is associated with this publication.
Abstract
© The Author 2014.Background: The iPrEx study demonstrated that combination oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) as preexposure prophylaxis (PrEP) protects against HIV acquisition in men who have sex with men and transgender women
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.